UK based diagnostics developer of early cancer tests Cizzle Biotechnology Holdings plc (LSE: CIZ) announced on Wednesday that it has signed a Letter of Intent with a leading UK medical diagnostic services provider working in partnership with the NHS to validate and verify its CIZ1B biomarker test for early lung cancer detection.

The collaboration, to be conducted in advanced NHS Foundation Trust laboratories, could result in the provider becoming Cizzle's exclusive UK supplier of the CIZ1B test, subject to regulatory approvals. Under the agreement, the provider will conduct validation and clinical assessments while Cizzle provides technical support under the supervision of Professor Dawn Coverley, the company's founder and Chief Scientific Officer. Successful validation will lead to negotiations for a Partnership Agreement covering commercialisation, co-branding and a revenue-sharing or licensing model across the UK and Europe.

The CIZ1B test, developed from Professor Coverley's research at the University of York, offers a non-invasive and cost-effective blood test for early-stage lung cancer. Cizzle aims to align its UK rollout with the NHS cancer plan to increase early diagnoses and improve survival rates.

The partnership follows the company's GBP150,000 funding secured in May 2025 from existing shareholder Frazer Lang to support European expansion. Cizzle has already licensed its CIZ1B technology in North America and the Caribbean under a deal worth USD2.4m in royalties and upfront fees.

Cizzle will also continue supporting its US partner, Cizzle BIO Inc, in achieving CLIA accreditation and completing clinical studies at Moffitt Cancer Center for patients with suspicious lung nodules.